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Background: Mouse models are used in the study of human disease. Despite well-known homologies, the difference
in immune response between mice and humans impacts the application of data derived from mice to human disease
outcomes. Nitric oxide synthase-2 (NOS2) is a key gene that displays species-specific outcomes via altered regulation of
the gene promoter and via post-transcriptional mechanisms in humans that are not found in mice. The resulting levels
of NO produced by activation of human NOS2 are different from the levels of NO produced by mouse Nos2.
Since both tissue redox environment and immune responsiveness are regulated by the level of NO and its interactions,
we investigated the significance of mouse and human differences on brain oxidative stress and on immune activation in
HuNOS2tg/mNos2−/− mice that express the entire human NOS2 gene and that lack a functional mNos2 compared to wild
type (WT) mice that express normal mNos2.
Methods/results: Similarly to human, brain tissue from HuNOS2tg/mNos2−/− mice showed the presence of a NOS2 gene
3′UTR binding site. We also identified miRNA-939, the binding partner for this site, in mouse brain lysates and
further demonstrated reduced levels of nitric oxide (NO) typical of the human immune response on injection
with lipopolysaccharide (LPS). HuNOS2tg/mNos2−/− brain samples were probed for characteristic differences in
redox and immune gene profiles compared to WT mice using gene arrays. Selected genes were also compared
against mNos2−/− brain lysates. Reconstitution of the human NOS2 gene significantly altered genes that encode
multiple anti-oxidant proteins, oxidases, DNA repair, mitochondrial proteins and redox regulated immune proteins.
Expression levels of typical pro-inflammatory, anti-inflammatory and chemokine genes were not significantly different
with the exception of increased TNFα and Ccr1 mRNA expression in the HuNOS2tg/mNos2−/− mice compared to WT
or mNos2−/− mice.
Conclusions: NO is a principle factor in establishing the tissue redox environment and changes in NO levels impact
oxidative stress and immunity, both of which are primary characteristics of neurodegenerative diseases. The
HuNOS2tg/mNos2−/− mice provide a potentially useful mechanism to address critical species- specific immune
differences that can impact the study of human diseases.
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The past five years have proven to be disappointing and
frustrating to pre-clinical scientists in the Alzheimer’s
field. Multiple therapeutics that worked to reduce amyl-
oid mediated pathology in established mouse models of
Alzheimer’s disease (AD) have not proven to be useful in
humans with AD and, in some cases, have made the dis-
ease outcomes worse [1-4]. The results of these and other
clinical trials have now driven the search for a better un-
derstanding of AD disease mechanisms and emphasize
the pressing need for re-evaluation of research directions
in the field. Recently, a critical avenue of research relevant
to neurodegeneration has been a subject of renewed inter-
est. Although immune changes in AD have been known
for many years, the importance of an immune response to
the disease process was unclear. This was despite convin-
cing evidence from Caleb Finch [5], W. Sue Griffin [6,7],
Piet Eikenlenboom [8], Patrick and Edith McGeer [9,10]
and others who showed that immune responses were
observed as an early and key pathological characteris-
tic of humans with AD. Data from genome-wide associ-
ation studies (GWAS) have now firmly established that
genes involved in the immune response are central to the
risk for development of late onset Alzheimer’s disease
[11-13]. These genes encode proteins that include apoli-
poprotein E (APOE) that serves as a global immune regu-
lator [14], complement receptor 1(CR1) that may mediate
Aβ clearance from the brain [15], CD33 (Siglec11) that
when expressed on microglia becomes neuroprotective
[16] and TREM2 with its downstream target TYROBP
(DAP12) that regulates multiple microglial functional
pathways [17,18]. The immune response in AD is clearly a
critical event in the disease process. Zhang et al. [17] using
an integrated network analysis of late onset AD-associated
genes showed that immune/microglia gene networks dem-
onstrated the strongest degree of disease association and
the highest correlation to AD neuropathology compared
to other gene subsets. Despite these exciting findings, we
still don’t understand how immune cells such as microglia
are involved in the initiation or progression of disease,
if and when their involvement changes with time or even
what type of response is generated by microglia (or other
immune cells) at different stages of AD.
Seok et al. [19] have re-enforced an additional dimen-
sion of complexity that impacts our methodologies we use
to understand how the brain’s immune response is in-
volved in neurodegenerative diseases such as AD. In their
controversial study, Seok and colleagues compared the
genomic responses of mice and humans during an acute
immune response resulting from endotoxemia, burns or
trauma. Their study demonstrated that correlations be-
tween mouse and human immune signaling pathways
were poor for these acute illnesses and at least for path-
ways that are commonly initiated by lipopolysaccharide(LPS), mouse gene changes were not predictive of human
gene changes for a similar disease initiation process.
More recently, this interpretation has been challenged by
Takao and Miyakawa [20]. Regardless, it is generally agreed
that not only are disease-based changes in immunity
a challenging issue, but also the models used to study
human immune responses during disease should be care-
fully considered.
The recognition that mouse immune processes are not
the same as human immune processes is clearly not new.
Mestas and Hughes in 2004 [21] defined a number of dif-
ferences in both innate and adaptive immune characteris-
tics between rodents and man. These differences include
Fc receptor subtypes, the action of IFNα on Th1 cells and
the involvement of the Th2 response in clearance of para-
sites. In 1995 our lab showed that cultured microglia and
macrophages from humans showed limited nitric oxide
(NO) production in response to immune stimuli that were
commonly used on mouse cells in culture such as LPS
or polyinosinic:polycytidylic acid (PIC) alone or in com-
bination with cytokines such as interferon- γ (IFNγ) or
interleukin-1β [22,23]. Microglia cultured from rodent
brains, however, are well known to produce robust levels
of NO when stimulated with the same induction agents.
NO is the product of the inducible iNOS protein that is
encoded by the NOS2 gene and serves defensive and regu-
latory roles in an immune response. Multiple other labs
have observed similar differences between NO production
in mouse and in human cells and a vigorous discussion on
the molecular mechanisms underlying these differences
has ensued over the intervening years [24-28]. An elegant
study by Guo et al. [29] demonstrated a reasonable
explanation for these differences. Guo, Geller and col-
leagues found binding sites for a microRNA (miRNA-939)
in the 3′untranslated region (UTR) of the human NOS2
gene. When these sites are bound to miRNA-939, a post-
transcriptional repression of iNOS protein expression
is initiated and NO production was thereby reduced.
While this may not be the sole mechanism for differences
between human and rodent NO production and differ-
ences in promoter regulatory activity also exist [25,30-32],
miRNA-mediated silencing may account for a large part
of the inability to readily stimulate and measure NO in
human macrophages and microglia.
Despite problems with species-specific responses, it is
equally clear that mouse models of disease facilitate the
mechanistic study of cellular and integrated systems at
multiple stages of a disease process. Animal models will
remain a valuable tool to understand human disease.
However, the translatability of these data derived from
mice to human is ultimately a question. Furthermore, the
lack of models that more closely resemble the human
immune environment remains a core problem. In addition
to differences in immune regulatory events [19,33,34],
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tion of the cell and tissue redox environment that also im-
pacts immunity [34,35].
One way to address these issues is to “humanize” mouse
models by replacing mouse genes with corresponding hu-
man genes. There are currently many examples of this type
of approach including multiple models of neurodegenera-
tive disease where a mutated gene is added in addition to
the mouse gene (for example, the APPsw-Tg2576 mice;
[36] or where the human gene replaces a large part of the
mouse gene with or without replacing the promoter region
of the gene (Apoe4 targeted replacement mice, [37]). Simi-
lar methodologies have been used for immune genes. The
choice of which mouse gene to alter depends on the dis-
ease process.
We have developed mouse models of AD that express
mutated human amyloid precursor protein (APP) and
also demonstrate human-like NO production when im-
mune stimulated. Our scientific rationale for this model
was based on the interrelationship between inflamma-
tion, oxidative stress and neurodegeneration [34,38]. NO
serves as a nodal point between inflammation and oxida-
tive stress, and when altered, results not only in a changed
brain redox environment [34,35], but also in altered im-
mune regulation, both of which impact human disease
[33,34]. The types of interactions and their products are
now well described in excellent reviews and will not be dis-
cussed here [39-43]. However, it is clear that both super-
oxide anion through oxidative events and NO through
both direct and indirect reactions regulate multiple pro-
teins and cellular pathways in a precise manner. These
pathways dictate immune regulation and immune defense
[34]. Because the direct and indirect reactions of NO are
dependent on the available concentration of NO, the
consumption of NO, for example by combination with
superoxide anion, significantly impacts the redox envir-
onment of the tissue and alters multiple NO-dependent
pathways [42-44]. By shifting the inherent NO level during
an immune response, the outcome is likely to provide a
unique subset of regulatory and defensive events that are
tailored to the individual species. Evolution has made this
shift for humans and rodents and has imposed a differ-
ence in NOS2 regulation between these species.
To better understand the importance of mouse and hu-
man Nos2 differences, we have generated a mouse model
that expresses the entire human NOS2 gene on a mouse
Nos2 knockout background [45]. This new mouse strain
has gene regulatory sites that, similar to the human NOS2
gene, are associated with reduced NO production. Here,
we show characteristic redox gene differences between
mice expressing a normal mNos2 gene and mice express-
ing only the huNOS2 gene. We also discuss the potential
impact of these gene differences on tissue redox balance
and immunity.Results
HuNOS2tg/mNos2−/− mice show 3′UTR binding sites,
miRNA-939 homolog and reduced NO production in vivo
Guo et al. [31] have shown that miRNA-939 binds to sites
in the 3′UTR region of the human NOS2 gene, thereby
altering the translation of iNOS protein and reducing
NO production. To determine if the human NOS2 gene
in HuNOS2tg/mNos2−/− mice expressed the appropriate 3′
UTR binding sites we PCR amplified the miRNA-939
binding region from DNA isolated from HuNOS2tg/
mNos2−/− brain tissue. Figure 1A shows the results of a
typical genotyping assay for 7 individual HuNOS2tg/
mNos2−/− mice and corresponding WT mice. The upper
band found in mice expressing the HuNOS2 gene
corresponds to a region of the mNos2 gene, which has
remained intact in the mNos2−/− strain despite the disrup-
tion to the mNos2 gene. The lower band corresponds to a
185 bp product containing the 3′UTR miRNA-939 bind-
ing region of huNOS2 gene.
Having demonstrated that HuNOS2tg/mNos2−/− mice
express the 3′UTR binding site that is characteristic of
the human NOS2 gene, we then used RT-PCR to detect
the presence of a miRNA-939 homolog in brain and liver
lysates from lipopolysaccharide (LPS)- treated HuNOS2tg/
mNos2−/− mice. LPS diluted into saline was injected intra-
venously (iv) to induce an immune response that in-
cludes induction of the NOS2 gene and immune-related
cytokines. Saline-injected mice were used as untreated
controls. At 7 hrs after injection, we assayed brain sam-
ples for miRNA-939 and used small nucleolar RNA-202
(snoRNA-202) as an endogenous control for microRNAs.
Figure 1B presents results from a typical PCR cycling reac-
tion and demonstrates the presence of miRNA-939 in
HuNOS2tg/mNos2−/− brain. We also examined the effect
of LPS treatment on the level of miRNA-939 homolog in
our mice. Figure 1C shows the average fold change (±sem)
in miRNA-939 in brain and liver samples after stimulation
with LPS. A similar LPS-mediated increase in miRNA939
levels was shown by Guo et al. [29] for human hepatocytes
in culture and in liver lysates from WT mice injected with
LPS or a cytokine mix.
Our previously published studies using LPS or cytokine-
stimulated primary cultures of peritoneal macrophages
derived from HuNOS2tg/mNos2−/− mice demonstrated a
significant decrease in the conversion of [H3] arginine to
[H3] citrulline [45], indicating reduced iNOS enzymatic
activity compared to WT mice. Human and mouse NOS2
have similar specific activity suggesting that changed activ-
ity is regulated via cellular processes [46]. In addition,
we showed that NO production in immune stimulated
cultured peritoneal macrophages was also significantly
decreased in HuNOS2tg/mNos−/− mice compared to
similarly treated WT mice. To show that in vivo NO
production was also altered we measured total nitrite
Figure 1 HuNOS2tg/mNos2−/− mice express both the 3′UTR
binding site and a miRNA-939 homolog involved in regulation
of the huNOS2 gene. A- PCR amplification of the 3′UTR region
containing putative binding sites for miRNA-939 of the human NOS2
gene in HuNOS2tg/mNos2−/− and WT mice. Lanes represent individual
mice. Lower bands in Lanes 2–8 are consistent with the human 3′UTR
region which is not observed in WT mice (lanes 9–17). B- Graph of PCR
product amount versus cycle number for amplification of miRNA-939
homolog product using small nucleolar (sno) RNA-202 as endogenous
controls. C- Relative change in miRNA-939 homolog levels in brain and
liver lysates at 7 hrs after injection of LPS compared to saline injected
lysates. Data points represent average fold change (±sem), n = 3 mice
each strain.
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HuNOS2tg/mNos2−/− mice compared to similarly treated
mNos2−/− and WT mice. All mice (36–40 weeks of age)
were intravenously (iv) injected with either 10 mg/kg
of LPS or saline (0.9% NaCl) via the tail vein and tis-
sues were collected at either 7,18 or 24 hrs post injection.
Figure 2A show mRNA levels for LPS-treated mice com-
pared to untreated (saline-injected) conditions for both
WT and HuNOS2tg/mNos2−/− mice brain lysates. As pre-
dicted, mRNA increased in both strains on LPS stimula-
tion, however, levels of expression were lower in mice
expressing the huNOS2 gene. We next compared nitriteand nitrate (NOx) levels in brain (Figure 2B) and liver
(Figure 2C) lysates derived from LPS-injected or saline-
injected WT mice to the levels of NOx found in lysates
from mNos2−/− and HuNOS2tg/mNos2−/− mice. As pre-
dicted, WT mice demonstrated a significantly in-
creased level of NOx in both brain and liver tissue
lysates with time after immune stimulation. However, nei-
ther mNos2−/− knockout mice nor HuNOS2tg/mNos2−/−
mice showed a measurable in vivo response to treatment
with LPS when compared to WT-Nos2 sufficient mice.
HuNOS2tg/mNos2−/− mice show a unique redox gene
profile
To better understand how reconstitution of the human
NOS2 gene in a mNos2−/− knockout background impacts
the redox and immune profile compared to WT mice
that normally express mNos2 and high levels of NO, we
performed a directed gene array analysis. For this experi-
ment RNA was extracted from brain lysates previously
prepared from the WT and HuNOS2tg/mNos2−/− mice
injected with either LPS (10 mg/kg) or saline. Quantitative
RT-PCR was performed on the cDNA using a custom
TaqMan Gene Expression Assay plate (Life Technologies).
The array was designed to evaluate a defined mixture of
redox and immune genes and three mice for each treat-
ment group at each time point were assessed. All CT
values were normalized to endogenous levels of 18sRNA
and average fold change values (RQ) were determined by
2(−ΔΔCt) method using either WT saline- injected or
HuNOS2tg/mNos2−/− saline- injected as the comparator
[47]. The resultant RQ values for LPS-treated HuNOS2tg/
mNos2−/− mice (here abbreviated HN) and WT mice sam-
ples were then compared at 7 and 24 hrs post-LPS injec-
tion. To better visualize the changes due to LPS treatment
for each mouse strain and at each time point, a heat map
was prepared using these ratios (Figure 3). Ratio values
were linearized by Log2 conversion, then subjected to
conditional formatting whereby Log2(RQ) values less than
0 were colored red (decreased expression) and Log2(RQ)
values greater than 0 were colored green (increased ex-
pression) according to the scale in Figure 3. Asterisks de-
note a statistically significant change due to LPS treatment
with respect to control (saline-injected) mice. In addition,
we compared the fold-change in expression levels in LPS
treated HuNOS2tg/mNos2−/− mice for each gene to the
corresponding fold-change found in WT mice. Statistically
significant changes for these data are shown only for the
24 hrs treatment point and are labeled on the heat map
with a delta (Δ) sign. Genes are also grouped according to
their known function.
LPS stimulation differentially altered the expression of
redox related genes in both a time and gene specific
manner in the HuNOS2tg/mNos2−/− mice compared to
WT mice. For example, as shown in the heat map, DNA
Figure 2 LPS-stimulated mRNA and NOx production in
HuNOS2tg/mNos2−/− mice. A. Comparison of the fold changes in
NOS2 mRNA levels for HuNOS2 and mNos2 (WT) mice. Brain lysates
were prepared from saline injected and LPS injected WT and
HuNOS2tg/mNos2−/− mice at 7 and 24 hrs. Average fold changes
(±sem) for LPS-treatment were determined using the average
saline-injected value as comparator. n = 3 mice/group. ** = p <0.01
using the unpaired student’s t test with significance set at p < .0.05.
B. Brain lysate levels of nitrite and nitrate (NOx) were measured in
HuNOS2tg/mNos2−/−, mNos2−/− and WT mice at 7, 18 and 24 hrs.
Saline- injected mice from each strain served as the 0 hrs time point.
Average NOx values (ng/ug protein ± sem) are shown where n = 6-9
mice/strain per time point. Significance with time within strain was
determined using one-way ANOVA while statistical significance
across genotypes was determined using two-way ANOVA (GraphPad
Software, San Diego CA). Significance was set at p ≤0.05. *p <0.05;
***p <0.001 for comparisons across strains; ###p <0.001 for comparisons
within strain. C. Analysis of NOx in liver lysates from the same
mice as above and under the same conditions. ***p <0.001 for
comparisons across strains; ###p <0.001 for comparisons within strain.
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damage such as Excision Repair Cross Complementation
2 (Ercc2) that encodes the XPD protein and Ercc6 that
encodes the Cockayne syndrome b (CSB) protein show
no significant gene induction in HuNOS2tg/mNos2−/−
mice at 7 hrs post-LPS injection. By 24 hrs, however, ex-
pression of these genes in response to LPS-injection in
HuNOS2tg/mNos2−/− mice was observed, indicating a
different time to response in HuNOS2tg/mNos2−/− mice
vs WT mice. Checkpoint homolog 1 (Chek1) and the
transcription factor p53 follow a similar pattern. The sig-
nificance of this delayed repair response to LPS in
HuNOS2tg/mNos2−/− mice is not clear, but it suggests
that NO levels affect the early phases of the innate im-
mune process in a species-specific manner. Similarly, we
find that anti-oxidant and oxidant genes show a signifi-
cantly higher or lower expression level in LPS-treated
HuNOS2tg/mNos2−/− mice at 24 hrs post-injection com-
pared to similarly treated WT mice. Selected genes are
also shown in Table 1. As predicted from the role of NO
as a regulator of oxidant/antioxidant balance, HuNOS2tg/
mNos2−/− mice show decreased expression (WT > HN) of
many antioxidant genes (peroxiredoxins, glutathione re-
ductase (Gsr), catalase (Cat)) concomitant with increased
expression of genes (HN > WT) associated with oxidative
pathways such as Cyba (the b subunit of the NADPH oxi-
dase), Lpo (lactoperoxidase) and eosinophil peroxidase
(Epx) compared to WT mice. This altered expression pat-
tern is indicative of a shift of the response at 24 hrs poten-
tially to a more “oxidative” environment that is regulated
by NO flux. Again, how this exactly impacts the disease
process remains unknown but it is likely to dictate a dif-
ferent overall redox microenvironment of affected cells.
To better understand how varying NO levels in vivo
might alter LPS-stimulated gene expression, we further
Figure 3 (See legend on next page.)
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Figure 3 Comparison of redox gene expression levels between LPS-simulated HuNOS2tg/mNos2−/− mice and WT mice. HuNOS2tg/mNos2−/−
and WT mice were injected with 10 mg/kg LPS, or with saline as a control, and brains were removed after 7 or 24 hours. RNA was extracted, reverse
transcribed, and target gene expression was measured by q-PCR. Fold changes (RQ) were determined for HuNOS2tg/mNos2−/− and WT mice using
appropriate saline-injected animals as the comparator for each mouse strain. RQ values were linearized by Log2 conversion, and then subjected to
conditional formatting whereby red cells denote lower expression and green cells denote higher expression according to the color scale. Significant
differences in gene expression for LPS treated as compared to same strain saline-injected controls were determined by student’s t-test (*p ≤0.05,
**p <0.01, ***p <0.001). Significant differences in gene expression between WT and HuNOS2tg/mNos2−/− mice at specific time points were determined
by student’s t-test (Δ p ≤0.05, ΔΔ p <0.01, ΔΔΔ p <0.001). n = 3 mice per group.
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(no NO) and compared these mRNA levels to the levels
found in high NO (WT mice) and to mice with “human”-
like levels (HuNOS2tg/mNos2−/−). Examples of gene
expression patterns are shown in Figure 4. We found
LPS-stimulated genes (cystathione-b- synthase; glutathione
peroxidase-3; Figure 4 A, B) that were significantly changed
only in WT mice compared to either HuNOS2tg/mNos2−/−
or mNOS2−/−, and thus appeared to be dependent on high
levels of NO production. Alternatively, heme oxygenase −1
(Ho-1) and heat shock protein 27 (Hspb2, Hsp27) were
specifically altered in the HuNOS2tg/mNos2−/− mice brain
(Figure 4 C, D). Ho-1 mRNA levels increased with LPS
treatment whereas no significant change in Ho-1 was
found for either WT or the mNos2 knockout mice. Basal
expression levels of Hsp-27, however, were increased inTable 1 LPS-stimulated gene expression differences
between HuNOS2-/-/mNos2-/- and WT mice brain at





*Prdx3 Periredoxin 3 WT>HN
Prdx4 Periredoxin 4 WT>HN
Prdx5 Periredoxin 5 WT>HN
Gsr Glutathione reductase WT>HN
Cyba NADPH oxidase Cytochrome- b subunit a HN>WT
Cat Catalase WT>HN
Epx Eosinophil peroxidase HN>WT
Gpx4 Glutathione peroxidase 4 HN>WT
Nqo1 NAD(P)H dehydrogenase 1-Quinone 1 WT>HN
Gsr Glutathione reductase WT>HN
*Lpo lactoperoxidase HN>WT
Ireb2 Iron responsive element binding protein 2 WT>HN
RAD51 RAD51 recombinase HN>WT
*Recql4 REC-q like protein 4 (helicase) ND
Hbq1 Hemoglobin theta 1 WT>HN
*IL-22 Interleukin 22 HN>WT
Rag2 Recombination activating gene 2 WT>HN
Slc38a1 Solute Carrier 38a1
(glutamine transporter)
WT>HN
*Gene analysis was confirmed by additional RT-PCR (See Figure 4).mice expressing human NOS2 but not in WT or mNos2−/−
mice. Finally, as shown in Figure 4 (E,F) mice lacking
mNos2 and thus unable to increase NO in response
to LPS showed significantly higher levels of lactoper-
oxidase (Lpo) and lower levels of aconitase1 (Aco1).
Gene changes between HuNOS2tg/mNos2−/− and WT
mice under non- immune stimulated conditions provide
insights into the potential physiological impact of an in-
herent background difference in WT mice that have
high levels of NO and in HuNOS2tg/mNos2−/− mice that
have low levels of NO. However, NOS2 is an inducible
gene and any non-stimulated change in brain expression
levels when the HuNOS2 gene is inserted into the mouse
genome is puzzling. NOS2 translation and transcription are
well-known to be regulated by disease-based immune acti-
vators including LPS and cytokines via multiple membrane
receptors. For the human gene, NOS2 gene expression
is also regulated by non ‘cytokine’- like factors includ-
ing β-catenin/Wnt2, epidermal growth factor (EGF), col-
ony stimulating factor 1 (CSF1) and hormones such as
testosterone [30,38,48]. Geller and colleagues [25,30] have
shown specific upstream sites in the human NOS2 pro-
moter that alter gene regulation. One of these sites medi-
ates basal promoter activity of the NOS2 gene and
functions independently of known cytokine responsive
regulatory elements in the gene promoter. The physio-
logical role of basal induction of the NOS2 gene in human
cells is not well studied but has been implicated in
changes that lead to cancer [48,49]. To determine if non-
stimulated “basal” changes could be found in mice ex-
pressing the human NOS2 gene we compared mRNA
levels of selected genes between saline- treated mNos2−/−
(where NO is not produced) and HuNOS2tg/mNos2−/−
mice that express a human NOS2 gene and promoter and
produce human levels of NO. Of the genes tested (Figure 4),
Hsp27 was found to demonstrate a significant change in
saline-treated (control) levels of mRNA expression with no
significant difference in LPS-stimulated mRNA expression.
Immune gene profiles are altered in mice expressing the
huNOS2 gene
We next determined if changes in the tissue redox re-
sponses in HuNOS2tg/mNos2−/− mice could also impact
cytokine production in the brain. Thus, gene expression
Figure 4 Comparison of gene expression for selected genes. Genes that showed changes in expression levels between WT and HuNOS2tg/
mNos2−/− mice were also examined for expression levels in mNos2−/− mice. Brain lysates were prepared from saline-injected (white bars) and
LPS-injected (black bars) mNos2 knockout mice as described and gene expression measured using qRT-PCR. Average fold changes (±sem) for
each gene in saline and LPS-treated conditions were determined using the average WT saline-injected value as comparator. Statistical significance
across genotypes and treatment was determined using two-way ANOVA (GraphPad Software, San Diego CA). Significance was set at p ≤0.05.
*p <0.05; **p <0.01 for comparisons with treatment; #p <0.05, ##p <0.01 for comparisons across strains. n = 5–6 mice per group.
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inflammatory cytokines were measured in HuNOS2tg/
mNos2−/− mice and compared to WT and mNos2−/− mice
at 24 hrs after LPS injection. We also measured the same
genes in brain lysates from the HuNOS2tg/APPSwDI/
mNos2−/− to understand if brain Aβ production and
accumulation altered cytokine mRNA levels when the
HuNOS2 gene is expressed. All mice were injected with
10 mg/kg LPS or saline and brain lysates prepared in the
same manner as described previously. Gene expression
levels are presented in Figure 5 as the average (±sem) fold
changes observed under untreated and LPS- treated con-
ditions. As shown, pro-inflammatory (Il-1β; TNFα, IL-6)
and anti-inflammatory (Ag1, IL-rn) mRNA levels signifi-
cantly increased with LPS- treatment in each of the mouse
strains examined (Figure 5 A-E). Genotype specific differ-
ences were also observed. Significantly greater responses
were observed in APPhuNOS2 mice for Il-6, in mNos2−/−mice for Ag1 and in HuNOS2tg/mNos2−/− mice for Tnfα.
Tgfβ failed to show a response to LPS in any of the mouse
strains (Figure 5F). Chemokine gene expression pat-
terns were dependent on the specific chemokine. Cx3cr1
mRNA expression (Figure 5G) was not significantly
altered by treatment with LPS in any of the mouse
strains. For Ccr2, LPS- treatment reduced levels of mRNA
expression in brain lysates from HuNOS2tg/mNos2−/−,
APPHuNOS2 and mNos2−/− mice but not in WT mice
(Figure 5H). However, increased LPS-mediated expres-
sion of Ccr1 was found only in the strains that expressed
HuNOS2tg/mNos2−/−. We also examined a microglia
marker that is found in patients with AD [9,10]. The Itgax
gene encodes the CD11c protein and was significantly
increased only in HuNOS2tg/APPSwDI/mNos2−/− mice
(Figure 5J). Finally, to determine if the production of Aβ
peptides and accumulation of amyloid altered nitrate
and nitrite levels in brain, we measured NOx levels as
Figure 5 Changes in immune gene expression levels in LPS-simulated HuNOS2tg/mNos2−/−; APPSwDI+/−/Hu NOS2tg+/+/mNos2−/−; mNos2−/−,
and WT mice. Brain lysates were prepared from saline-injected (gray bars) and LPS-injected (black bars) mice from each of the 4 different strains at
24 hrs. Saline-injected mice from each strain served as the corresponding 0 hrs time point. Average fold changes (±sem) for each gene were
determined using the average WT saline-injected value as comparator. n = 5–6 mice per group. Panels A-F- cytokine genes; Panels G-I-
chemokine genes - J- gene marker of activated microglia- integrin alpha10 (CD11c). Statistical significance was determined using two-way ANOVA
with genotype as the between strain factor and treatment as the within strain factor (GraphPad Software, San Diego CA). Significance was set at
p ≤0.05. *p <0.05; **p < 0.01; ***p <0.001; #p <0.05; ##p <0.01; ###p <0.001. K- APP mutations that increase Aβ production and amyloid
deposition do not increase brain NOx levels. Brain lysates were prepared from saline injected and LPS injected APPSwDI/mNos2−/− and APPSwDI+/−/
Hu NOS2tg+/+/mNos2−/− mice (see methods for details on mouse strains). NOx brain lysate levels in LPS-stimulated WT mice serve as the positive
control for NO production. Data are presented as the average NOx values ± sem (n = 4–6 mice per group). Significant differences were determined for
each tissue type separately using two-way ANOVA with genotype as the between strain factor and treatment as the within strain factor. #p <0.05.
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HuNOS2tg/APPSwDI/mNos2−/− and APPSwDI/mNos2−/−
mice using WT as the positive control. No significant
changes in NOx levels were observed for mice from either
of the APP strains (Figure 5K).
The observed changes in brain gene expression between
WT, HuNOS2tg/mNos2−/− and mNos2−/− mice suggested
that strain-dependent physiological differences may also
be found. LPS treatment is well known to affect the brain
/blood interface by increasing small hemorrhages resulting
in brain accumulation of red blood cells and hemosiderin,a break down product of heme iron [50-52]. Since
the blood brain barrier integrity is regulated, in part, by
NO-dependent metalloprotease (MMP) activity [52,53] we
compared the average number of brain microbleeds per
section (±sem) in WT, HuNOS2tg/mNos2−/− and mNos2−/−
mice. Microbleeds were assessed using Prussian blue histo-
chemistry as previously described [51,52] and categorized
as “small” (Figure 6A) or “large” (Figure 6B). As shown in
Figure 6C, LPS-treatment initiated a significant increase in
large microbleeds compared to saline-treated (control)
brains in both HuNOS2tg/mNos2−/− and mNos2−/− mice.
Figure 6 Mouse stain specific differences in brain microhemorrhage. The total number of microhemorrhages per brain section were
calculated for HuNOS2tg+/+/mNos2-/-; mNos2-/-, and WT mice under saline treated (control-gray bars) and LPS-treated (black bars) conditions.
Panel A; B- typical view of small (<20 microns; A) and large (>20 microns; B) microbleeds observed in brain sections using Prussian blue
histochemistry to identify hemisedrin deposits. Panel C; D- Data represent the average number (+ sem) of microbleeds/section (n- 4-7 mice
of each strain) for control and LPS-treated mice. Significant differences were determined using two-way ANOVA with genotype as the between strain
factor (^p<0.05) and treatment as the within strain factor (#p < 0.05; ##p<0.01).
Hoos et al. Molecular Neurodegeneration 2014, 9:50 Page 10 of 15
http://www.molecularneurodegeneration.com/content/9/1/50Mice lacking Nos2, however, showed a significant increase
in untreated control brain bleeds when compared to un-
treated HuNOS2tg/mNos2−/− and mNos2−/− brains. The
average untreated value from mNos2−/− brains was not dif-
ferent compared to LPS-treated mNos2−/− brains. A similar
pattern was observed for small bleeds in terms of the strain
differences. However, the number of small bleeds was sig-
nificantly lower with LPS treatment (Figure 6D).
Discussion
NO and superoxide anion are primary redox molecules
that establish and regulate tissue redox balance through
direct and indirect mechanisms of action. Both NO and
superoxide anion are also central components of immun-
ity with regulatory and defensive roles. Thus, it is likely
that species differences in production or consumption of
either NO or superoxide anion will have evolutionary sig-
nificance. As a reactive molecule that interacts with mul-
tiple proteins and has a relatively long diffusion distance,
NO is particularly well suited to impact cellular pathways.
The outcome of these reactions is now well known to be
dependent on the level of NO [34,42,48,54,55]. Thus, un-
derstanding how and when NO levels change in a tissue is
not only critical to deciphering redox regulated mecha-
nisms but also is critical to unraveling immune processes
and immune pathology.
The discovery of miRNA-939 mediated regulation of
human iNOS protein translation by Guo et al. [29] has
provided a realistic mechanism to explain a long term
conundrum: Why is iNOS mediated production of NO
different between human and rodent? Our data support
their finding and further directly show that these differ-
ences in NO production impact the redox, immune and
physiological signature of the brain. This was accom-
plished by reconstituting human NOS2 into a mouse
Nos2 knockout model, thus providing a useful tool to
study NOS2/NO related responses that are relevant tohuman disease in an in vivo as well as in vitro setting.
Our data from HuNOS2tg/mNos2−/− mice clearly show
the presence of the binding site for miRNA-939 in the
3′UTR region of the HuNOS2 gene and the presence of
a miRNA-939 homolog in the brain, thus recreating a
more human-like condition. While C57Bl/6 mice express
miRNA-939, they lack the binding site in the gene and the
additional regulatory complexity found in the human
NOS2 gene promoter. Geller and colleagues [25,30] have
also described unique promoter sites in the human gene
that involve non-cytokine based regulatory elements and
elicit basal production of NO by NOS2. This difference in
NO regulation implies a more varied and complex pro-
duction of NO in human tissues.
The inability to readily measure nitrite and nitrate levels
as a surrogate marker of NO production in human im-
mune cells has provided an increased level of difficulty in
charting NO’s involvement in specific pathways. As shown
in this study, LPS-mediated stimulation of human NOS2
in vivo does not result in measureable increases in brain
lysate levels of nitrite and nitrate, the commonly used in-
dicators of NO production. Nitrate and nitrite are clearly
not the only reaction product of NO, however, and other
reactive nitrogen species are produced as a result of
human NOS2 activation during an immune response
[39-41]. The directed gene array for HuNOS2tg/mNos2−/−
mice was designed to provide additional insight into
the spectrum of pathways that may be differentially acti-
vated by human NOS2 vs mouse Nos2. We specifically
chose redox based genes to profile because of NO’s inher-
ent redox activity and the role of redox-based regula-
tion in inflammation. In addition, neurodegenerative
diseases of aging such as Alzheimer’s disease have oxida-
tive stress as a primary component [56-58]. A similar di-
rected array approach has recently been used to delineate
redox genes that are changed in humans with Multiple
Sclerosis [59].
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mice expressing reconstituted huNOS2 produced a sta-
tistically significantly different pattern of redox gene ex-
pression than WT mice. The exact inter-relationships
between NOS2 expression levels and specific gene ex-
pression levels such as cystathione b synthase (Cbs) and
glutathione peroxidase 3 (Gpx3) are not precisely de-
fined here. For some genes such as Cbs, however, direct
connections to NO are known. For example, the enzym-
atic activity of Cbs protein is reduced when NO binds to
the heme site of the protein, thereby altering the transul-
furation pathway and the production of either hydrogen
sulfide (H2S) or glutathione (GSH) [60]. These data coupled
with the increased expression of glutathione peroxidase-3
and glutathione reductase in only LPS-treated WT mice
imply a regulatory cross talk between glutathione, H2S
and high levels of NO which may not be observed in
either the mNos2−/− or HuNOS2tg/mNos2−/− strains where
NO generated via NOS2 is low.
Two other important and specific points can be gleaned
from our data set. First, re-constitution of the human
NOS2 gene restores gene expression changes that occur as
a result of mNos2 depletion. For example, genes such as
Lpo and Ag1 are elevated only in mNos−/− mice. In mice
expressing human NOS2 mRNA, both Lpo and Ag1 ex-
pression levels are restored to the WT equivalent. These
data support the functionality of the HuNOS2 gene in the
mNos−/− mouse background. Secondly, the human NOS2
gene shows unique characteristics that are not found in ei-
ther WT or mice lacking mNos2. For example, three key
genes associated with disease, that is, heme-oxygenase 1
(Ho1), TNFα and Ccr1 are upregulated in HuNOS2tg/
mNos2−/− mice brain compared to either WT or mNos−/−
mice. These changes are likely to impact both the re-
sponse to hypoxia and the response of the brain to im-
mune challenge. The presence of human NOS2 also
mitigates the apparently “leaky” cerebral vessels found in
mNos2−/− mice. Increased constitutive levels of both large
and small microglia bleeds were observed in knock-out
mice. Although LPS altered the number of hemorrhage
sites in WT and HuNOS2tg/mNos2−/− mice in a complex
manner, addition of the human NOS2 gene prevented
these changes under normal, non-LPS simulated levels,
thus mimicking WT mice.
Differences in NO production and its complex action in
the brain’s redox environment clearly contribute to the
frequently conflicting data and disparate views of NO’s
role in disease, particularly when mouse models are used.
For neurodegenerative disease, NO is commonly viewed
as a contributor to neuronal death in the brain through its
ability to interact with superoxide ion to form reactive
oxygen species that kill the cell [61,62]. A good example
of this is the expression of iNOS in neurons in APP mouse
models of AD and in patients with AD. Cortical neuronsfrom the APPSw (Tg2576) mouse model of AD show
iNOS immunoreactivity around amyloid deposits and in
neurons associated with intracellular Aβ [63]. While foot-
prints of oxidation are found in this micro-environment,
the primary event that generates reactive oxygen species
may actually be the loss of NO’s role as a superoxide scav-
enger to reduce oxidative stress [42,64]. Local oxidants
such as reactive iron can interact with NO, leading to the
formation of nitrotyrosine and reducing local NO levels
[65]. In mouse brain where NO levels are likely to be high,
the impact of the loss of NO in the environment will be
different than in human brain where the inherent levels of
NO generated by iNOS are likely to be restricted by the
complexity of the NOS2 gene promoter and by miRNA
regulation of translation. Rodrigo et al. [63] clearly show
that increased expression of iNOS in APPSw mice is ac-
companied by increased Aβ and oxidative outcomes, but
these are not accompanied by neuronal death. APPSw
Tg2576 mice do not show neuronal loss [66]. In contrast,
the removal of mNos2 as shown in the APPSw/NOS2−/−
mice and the APPSwDI/NOS2−/− mice recreate a NO –
poor micro-environment and do demonstrate neuronal
death. We also have recently shown that reconstitution of
human NOS2 into mice expressing mutated human APP
and that lack mNos2 also proceed to neuronal loss [67],
further suggesting a critical role of NO levels. Fernandez-
Vizarra [68] has carefully examined the expression of
nNOS and iNOS at different stages of AD in neurons
from humans with AD. Interestingly, their data demon-
strated an increasing level of expression of nNOS followed
by increasing ecotopic expression of iNOS in cortical neu-
rons. They also observed that the increased expression of
NOS enzymes with progression of AD pathology was fre-
quently accompanied by nitrotyrosine immunoreactivity
but was only rarely associated with signs of neuronal
death. They concluded that the presence of NO was pro-
tective until “oxidative” events became a dominant cellular
pathology. The inherently different regulation of NO
levels produced by human iNOS during immune activa-
tion as we show herein and/or the consumption of argin-
ine, the sole substrate of iNOS are likely to be additional
factors that lead to the worsening pathology in humans
with AD. Thus the levels of NO and its perspective chem-
ical biology in the microenvironment is an important de-
terminant of outcome.
Mouse genetic models are, and undoubtedly will re-
main, a significant tool to study neurodegeneration and
neurological disease. The importance of their contribu-
tion to our understanding of the disease process in turn
depends on how the genetic change enables production of
a pathological pathway that resembles the pathway found
in humans. The importance of this question ultimately de-
pends on the degree of association of the gene changes
with disease. As discussed previously, Zhang’s [17] data
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samples from humans with AD provide important in-
sights. Their studies clearly show a dominant contri-
bution of microglial/immune genes to multiple clinical
co-variants found in patients with AD. However, NO me-
diated network associations with AD pathology are min-
imal. It is likely, then, that consideration of differences
between human and mouse NOS2 and the impact this has
on the brain’s redox environment may be useful in study-
ing human disease including AD.
Methods
Animals
All animal experiments were performed in accordance
with protocols approved by the Institutional Animal Care
and Use committee at Duke University Medical Center
under the NIH Guide for the Utilization and Care of
Vertebrate Animals Used in Testing, Research and Training.
Mice strains: HuNOS2tg+/+/mNos2−/− mice
The HuNOS2tg+/+/mNos2−/− strain was developed and
characterized by Vitek et al. as described [45].
APPSwDI+/−/Hu NOS2tg+/+/mNos2−/− mice
Homozygous APPSwDI/mNos2−/− (CerebroVascular amyloid-
Nos2−/− or CVN-AD) mice were produced by crossing
mice expressing the vasculotropic Swedish K760N/M671L,
Dutch E693Q and Iowa D694N human APP muta-
tions under control of the Thy-1 promoter with mNos2−/−
(B6 129P2NOS2tau1Lau/J) mice [45]. These mice were then
crossed to HuNOS2tg+/+/mNos2−/− mice to generate the
APPSwDI+/−/Hu NOS2tg+/+/mNos2−/− strain.
Control mice
mNos2−/− (B6 129P2NOS2tau1Lau/J) and C57Bl/6 WT
mice were purchased from Jackson Laboratory, Bar Harbor
ME and produced through the barrier breeding colonies
at Duke University. All mice were genotyped in a stand-
ard fashion.
LPS treatment
Mice between the ages of 36–40 weeks of age (mixed
genders) were iv injected with 10 mg/kg LPS or saline
(0.9% NaCl) via the tail vein. Mixed genders were used in
the analyses and gender based-differences were not inves-
tigated. Mice were allowed to recover on heated pads and
then were humanely euthanized at 7 and 24 hrs after the
injection with a lethal mixture of ketamine/xylazine. Each
mouse was intracardially perfused with approximately 25
mls of phosphate buffered saline (PBS). Hemispheres from
perfused brains and 2–3 lobes from each liver were then
rapidly removed, immediately frozen in liquid nitrogen
and the cryo-preserved tissue was pulverized under liquid
nitrogen for use in the assays. The remaining hemisphereswere fixed in 4% paraformaldehyde and passed through
sucrose gradients for sectioning on a freezing microtome.
Prussian blue staining
Sagittal sections (25 microns) were cut from fixed brain,
mounted and air-dried on slides for staining using the
Perls protocol. After rehydration, sections were reacted
with acidic potassium ferrocynanide (2 gm/100 mls) for
30 mins. Sections were then counterstained with neutral
red. The number of microbleeds was counted at 20 ×
magnification for 4 complete brain sections/mouse lo-
cated between 0.6-2.04 mm lateral to the bregma for a
minimum of 4 mice per strain. Microbleeds were identi-
fied as bright blue spots and were separated into two
categories; large (>20 microns) and small (<20 microns)
(see Figure 6).
NOx assay
For the NOx assay 40 mg of frozen pulverized brain or
liver tissue from each brain were boiled in 250 μl PBS
buffer for 10 min. After centrifugation to pellet, total ni-
trite and nitrate (NOx) content of the supernatants were
measured using a Sievers Nitric Oxide Analyzer under
reduction by vanadium (III) chloride (VCl3) in 1 N HCl,
heated to 95°C [69]. NOx levels were normalized to total
protein content of the supernatants as determined by
BCA assays.
qRT-PCR
Total RNA was extracted from approximately 40 mg
of frozen pulverized brain tissue, which was homogenized
using a Bullet Blender with RNase free 0.5 mm zirco-
nium oxide beads (Next Advance) in TRIzol reagent (Life
Technologies). cDNA was produced using the cDNA
High Capacity kit (Life Technologies) according to the
manufacturer’s instructions. Real-time PCR was performed
using TaqMan Gene Expression assays (Life Technologies)
also according to the manufacturer’s instructions and as
previously described [70]. Data were normalized to ei-
ther 18 s or ß-actin. Specific miRNA was reverse tran-
scribed using the TaqMan MicroRNA Reverse Transcription
Kit (Life Technologies) and the specific RT primer sup-
plied with each TaqMan miRNA assay. Quantitative PCR
was then run using the BioRad CFX96 Touch Real Time
PCR detection system. Average fold change values (RQ)
were determined by 2(−ΔΔCt) method using saline injection
as the comparator for individual strain samples [47].
Primers: Primers for WT mNos2 were: Forward 5′-
TTA CGT CCA TCG TGG ACA GC-3′and for Reverse
5′-TGG GCT GGG TGT TAG TCT TA-3′. Primers for
the human 3′UTR were: Forward- 5′ CCC CCA GCC
TCA AGT CTT ATT TC-3′ and for Reverse- 5′-CAG
CAG CAA GTT CCA TCT TTC AC-3′. Primers for
dectection of miRNA-939 were purchased as a TaqMan
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Technologies.
Statistical analysis
Data are presented as average values ± SEM. Where ap-
propriate, significant changes within strain were deter-
mined using student’s t-test or one-way ANOVA while
statistical significance between strains and treatments was
determined using two-way ANOVA (GraphPad Software,
San Diego CA). Significance was set at p ≤0.05.
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